SPECIAL ARTICLE
Bupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder

https://doi.org/10.1097/00004583-199505000-00017Get rights and content

ABSTRACT

Objective

In the treatment of attention-deficit hyperactivity disorder (ADHD), the efficacy of the tricyclic antidepressants and monoamine oxidase inhibitor antidepressants has been compared with that of both placebo and the stimulants (methylphenidate and/or dextroamphetamine). However, the effectiveness of bupropion has been contrasted only with placebo. The primary aim of this study was to contrast the efficacy of bupropion with that of methylphenidate in the treatment of ADHD.

Method

A double-blind, crossover design was used in this study. After a 14-day medication washout period, 15 ADHD subjects (7 to 17 years old) were randomized to either methylphenidate or bupropion for 6 weeks, washed out for an additional 2 weeks, and then “crossed over” to the other drug. Methylphenidate was titrated to the maximum effective dose of 0.4 to 1.3 mg/kg per day (mean 0.7 mg/kg per day) and bupropion was titrated to an effective dose ranging from 1.4 to 5.7 mg/kg per day (mean 3.3 mg/kg per day).

Results

Both methylphenidate and bupropion produced significantly greater (p < .001) and equivalent improvement on the lowa-Conners Teacher's Rating Scale according to both the subjects' parents and teachers. The same pattern of improvement was also noted for improvement on the Clinical Global Impression Scale, Kagan's Matching Familiar Figures Test, Continuous Performance Test, Children's Depression Inventory, Children's Manifest Anxiety Scale, and Rey Auditory-Verbal Learning Test.

Conclusions

In this double-blind, crossover trial, bupropion and methylphenidate were both effective and did not differ in their overall efficacy as treatments for ADHD.

REFERENCES (42)

  • TH Clay et al.

    Clinical and neuropsychological effects of the novel antidepressant bupropion

    Psychopharmacol Bull

    (1988)
  • C Conners

    The continuous performance test

    Psychopharamcol Bull

    (1965)
  • SR Dager et al.

    A case of bupropion-associated delirium (letter)

    J Clin Psychiatry

    (1990)
  • J Davidson

    Seizures and bupropion: a review

    J Clin Psychiatry

    (1989)
  • M Donnely et al.

    Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urine catecholamine levels and clinical response

    Clin Pharmacol Ther

    (1986)
  • AJ Finch et al.

    Multidimensionality of anxiety in children. Factor structure of the Children's Manifest Anxiety Scale

    J Abnorm Child Psychol

    (1974)
  • BD Garfinkel et al.

    Methylphenidate and caffeine in the treatment of children with minimal brain dysfunction

    Am J Psychiatry

    (1975)
  • RN Golden

    Psychoses associated with bupropion treatment

    Am J Psychiatry

    (1985)
  • JD Griffith et al.

    Bupropion: clinical assay for amphetamine-like abuse potential

    J Clin Psychiatry

    (1983)
  • W Guy

    Clinical Global Impression (CGI) Scale

    ECDEU Assessment Manual for Psychopharmacology, Revised (NIMH Publication ADM 76–338)

    (1976)
  • RD Heustis et al.

    Caffeine versus methylphenidate and d-amphetamine in minimal brain dysfunction: a double blind comparison

    Am J Psychiatry

    (1975)
  • Cited by (235)

    • Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period

      2018, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      Our findings also reveal a sex-dependent anxiolytic effect of MP as demonstrated by a greater proportion of time spent in the open arms of an elevated plus maze in the female HD group compared to the female water group. This finding is concordant with previous reports of MP-induced anxiolytic effects both from our team (Thanos et al., 2015; Robison et al., 2017b), and others (Barrickman et al., 1995; Bouffard et al., 2003; Zhu et al., 2010). As expected during the abstinence phase, we found no significant differences in anxiety-like behaviors between the treatment and control groups, again demonstrating the recoverability of the effect of MP.

    • The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial

      2014, Psychiatry Research
      Citation Excerpt :

      Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that acts on the primary serotonin transporter and the allosteric serotonin transporter site (Zhong et al., 2012). Bupropion has been shown to exert positive effects on a wide range of cognitive functions including memory (Conners et al., 1996; Evins et al., 2005; Barrickman et al., 1995), and has been reported to exert a superior effect to SSRIs on memory in a naturalistic study of individuals with MDD (Gualtieri and Johnson, 2007; Gualtieri et al., 2006). However, longitudinal investigations of bupropion׳s effects on memory in individuals with MDD are limited.

    View all citing articles on Scopus
    View full text